Fremanezumab for preventing migraine – guidance (TA631)

This is recommended for use in adults, only if migraine (MG) is chronic (≥15 headache days/month for >3 months with ≥8 of those having features of MG), and if ≥3 preventive drug treatments have failed. It should be stopped if MG frequency does not reduce by ≥30% after 12 weeks


National Institute for Health and Care Excellence